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Introduction {#sec1}
============

Polyubiquitination of proteins is an important posttranslational modification that can lead to a variety of cellular outcomes. The best-studied role of ubiquitination is as a proteasomal degradation tag, but ubiquitin (Ub) also has many non-degradative roles ([@bib47], [@bib58]). This versatility originates in part from the ability of Ub to form distinct polyUb chains. Ub can be ubiquitinated at any of eight primary amines (on the N-terminal amino group of M1 or the side chains of K6, K11, K27, K29, K33, K48, and K63), and all eight Ub linkage types co-exist in cells ([@bib40]). As a consequence, Ub chains have a vast array of architectures.

Cells utilize distinct Ub linkages in different signaling contexts, which invokes the need for linkage specificity at three levels: assembly; recognition; and disassembly. Linkage-specific assembly of polyUb is mediated by a subset of E2-conjugating enzymes and E3 Ub ligases ([@bib59], [@bib62]). Particularly interesting are E3 enzymes of the HECT and RBR families, because these often assemble Ub chains in a linkage-specific fashion. Once a Ub chain is formed, it is recognized by Ub-binding domains (UBDs) ([@bib17]), and this can occur in a linkage-specific manner. Selective UBDs for five out of the eight linkage types are known to date ([@bib47], [@bib58]). Finally, deubiquitinases (DUBs) disassemble the Ub chains, and some cleave chains with high linkage selectivity ([@bib6], [@bib29]).

The most abundant Ub chain types are K48-linked chains, which target proteins for proteasomal degradation, and K63-linked chains, which have non-degradative roles in intracellular trafficking, kinase signaling, DNA damage response, and other processes. The remaining six linkages, so-called "atypical" chains, are less abundant, but first roles are emerging ([@bib47], [@bib58]). For example, K6- and K33-linked chains were shown to increase after DNA damage ([@bib10]), and earlier data linked K6 linkages to the E3 Ub ligase BRCA1 ([@bib32], [@bib55]). K6 chains assembled by the RBR E3 Ub ligase Parkin were also shown to be important for mitophagy ([@bib9], [@bib36], [@bib37]), which is antagonized by the K6-selective, mitochondrial DUB USP30 ([@bib2]).

A main reason that less abundant chain types are still understudied is the current lack of tools to enable linkage-specific detection. Linkage-specific antibodies have been generated for five of the eight Ub chain types ([@bib26], [@bib27], [@bib35]; [Figure 1](#fig1){ref-type="fig"}A) and were instrumental to study K48-/K63-chain editing ([@bib35]), the importance of K11 chains in cell cycle regulation ([@bib26]), and M1 chains in inflammation ([@bib11]), respectively. Especially for linkages without known endogenous regulators, the generation of linkage-specific detection reagents is crucial.Figure 1Linkage Specificity of Affimers(A) Overview of Ub linkages with available linkage-specific antibodies.(B) Structure of general affimer scaffold (purple) with randomized loops (pink) that is used in phage display (PDB: [4N6U](pdb:4N6U){#intref0150}).(C) ITC titration of K6 affimer (5 μM; in cell) against K6 diUb (30 μM in syringe; left) and K33 diUb (30 μM in syringe; right), showing plots of raw heat (top) and derived isotherms (bottom) with fitted curve (red).(D) As in (C) but with K33 affimer.(E) SPR measurements of K6 affimer (10 μM) injected onto a chip where monoUb (black), M1 diUb (green), and K6 diUb (cyan) are immobilized.(F) Silver stain input of purified diUbs and western blot with biotinylated K6 affimer.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Here, we describe linkage-specific Ub affinity reagents for K6- and K33-/K11-linked chains, which were derived from non-antibody protein "affimer" scaffolds. Crystal structures of affimers bound to their cognate diUb reveal how they mimic naturally occurring linkage-specific UBDs and explain their linkage specificity. Guided by these structures, initial affimers were improved, and the resulting reagents are shown to be useful in a variety of applications. Using affimers in western blotting in combination with mass spectrometry reveals that the RBR E3 ligases RNF144A and RNF144B assemble predominantly K6-, K11-, and K48-linked chains *in vitro*. We further show that these affimers specifically recognize their cognate linkage also in a cellular background. In pull-downs using affimers to enrich K6 chains from cells, we identify the HECT E3 ligase HUWE1 and go on to show that HUWE1 also assembles K6-, K11-, and K48-linked chains *in vitro*. Interestingly, HUWE1^−/−^ or HUWE1 knockdown cells show significantly reduced levels of K6 chains, indicating that HUWE1 is a major source of cellular K6 chains. Further, we show that mitofusin-2 (Mfn2), a known substrate of HUWE1, is modified with K6 chains in a HUWE1-dependent manner.

Results {#sec2}
=======

Linkage-Specific Tools for Atypical Ubiquitin Chains {#sec2.1}
----------------------------------------------------

Ub-specific antibodies are notoriously difficult to generate in animals due to the high identity of Ub between species, and as a consequence, most available linkage-specific antibodies ([Figure 1](#fig1){ref-type="fig"}A) were selected using phage display ([@bib26], [@bib27], [@bib35]). Affimer technology provides an alternative route to generate specific high-affinity reagents. Affimers are 12-kDa non-antibody scaffolds based on the cystatin fold ([Figure 1](#fig1){ref-type="fig"}B; [@bib50], [@bib51]), in which randomization of surface loops enables the generation of large (10^10^) libraries, against which epitopes can be screened and binders can be selected. We characterized affimers against K6- and K33-linked diUb generated by Avacta (Wetherby, UK), and performed isothermal titration calorimetry (ITC) measurements on both affimers against K6- and K33-linked diUb. We found that the K6 affimer bound tightly to K6 diUb, whereas no binding could be detected to K33 diUb ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}A--S1C). Similarly, the K33 affimer bound K33 diUb but failed to detectably interact with K6 diUb as judged by ITC ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}C). Interestingly, the ITC measurements indicated the formation of a 2:1 affimer:diUb complex (n = 0.46 for K6 affimer and n = 0.44 for the K33 affimer), suggesting that the affimer dimerized for diUb binding. Qualitative kinetic analysis by surface plasmon resonance (SPR) on the K6 affimer showed that linkage specificity is achieved through very low off rates only for the cognate diUb ([Figure 1](#fig1){ref-type="fig"}E). We next tested site-specifically biotinylated affimers in western blotting against diUb of all linkage types. Indeed, the K6 affimer detected K6 diUb with high linkage specificity ([Figure 1](#fig1){ref-type="fig"}F) and only showed weak off-target recognition of other chain types, although cross-specificity was more pronounced with tetraUb ([Figure S1](#mmc1){ref-type="supplementary-material"}D). In contrast, the K33 affimer did not lead to any detectable signal by western blotting ([Figure S1](#mmc1){ref-type="supplementary-material"}E). The discrepancy in K33 linkage detection in ITC and western blotting is likely due to the different concentrations used in these experiments (50 nM in western blotting and 5 μM in ITC), which could affect, for example, the dimerization equilibrium.

Crystal Structures Explain Affimer Specificity {#sec2.2}
----------------------------------------------

To understand the observed linkage specificities, we determined crystal structures of the K6 and K33 affimers bound to their cognate diUb at 2.5 Å and 2.8 Å resolution, respectively ([Figures 2](#fig2){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}; [Table 1](#tbl1){ref-type="table"}). Both complexes show a conceptually similar interaction between affimers and diUb: each affimer molecule binds one Ub molecule and the affimer dimerizes to bind the two Ub moieties of a diUb in a linkage-specific manner ([Figures 2](#fig2){ref-type="fig"}A--2F and [S2](#mmc1){ref-type="supplementary-material"}A--S2C). The variable loops are responsible for dimerization as well as Ub recognition, and specific dimerization provides two binding sites for Ub I44 patches with a defined distance and relative orientation, leading to specific, high-affinity recognition. Other diUb linkages can only be bound by one affimer at a time, which significantly reduces the affinity. This is reminiscent of naturally occurring UBDs that provide two binding surfaces, and only the cognate linkage is able to occupy both simultaneously ([@bib21]).Figure 2Structures of Linkage-Specific Affimers with Their Cognate diUbs(A) Crystal structure of K6 affimer (shades of purple) bound to K6 diUb (shades of cyan) at 2.5 Å resolution. The variable loops (pink) contact the Ile44 patch (blue) on Ub.(B) Schematic of structure in (A) with indicated N and C termini.(C) Close up of the interaction in the K6 affimer:K6 diUb structure, showing hydrophobic interactions mediated by the variable loops (pink) of the affimer.(D) Crystal structure of the K33 affimer (shades of purple) bound to K33 diUb (shades of orange) at 2.8 Å resolution. The affimer dimerizes distinctly from the K6 affimer (see A) to bind diUb. Variable regions (pink) interact with the Ile44 patch (blue) of the Ub moieties.(E) As in (B) but for the K33 affimer:K33 diUb structure.(F) As in (C) but for the K33 affimer:K33 diUb structure.(G--I) Structures of one affimer bound to Ub, showing relative orientations of the bound Ub, as observed in the K6 affimer (G) and K33 affimer (H) structures and in the overlay (I).(J) Overlay of the K33 affimer:K33 diUb structure with previously determined K11 diUb structure (magenta; PDB: [3NOB](pdb:3NOB){#intref0155}).(K) ITC measurement of K33 affimer (5 μM in cell) against K11 diUb (30 μM in syringe).See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table 1](#tbl1){ref-type="table"}.Table 1Data Collection StatisticsK6 Affimer: K6 diUbK33 Affimer: K33 diUbK33 Affimer: K33 diUbPDB: [5OHM](pdb:5OHM){#intref0160}PDB: [5OHV](pdb:5OHV){#intref0165}PDB: [5OHL](pdb:5OHL){#intref0170}**Data Collection**BeamlineESRF ID23-2Diamond I04Diamond I04-1Space group*P* 1*H* 3*P 2*~*1*~*a*, *b*, *c* (Å)60.5, 69.7, 99.3120.3, 120.3, 69.955.9, 149.6, 73.8α, β, γ (°)79.8, 79.8, 83.190, 90, 12090, 110.4, 90Wavelength (Å)0.8729000.9794900.917410Resolution (Å)48.23--2.50 (2.59--2.50)60.14--2.80 (2.90--2.80)48.46--3.80 (3.936--3.80)*R*~merge~0.06 (0.26)0.235 (0.794)0.237 (0.779)*I*/σ*I*8.2 (2.4)5.0 (2.0)3.8 (1.5)*CC*~*1/2*~0.996 (0.791)0.978 (0.679)0.962 (0.665)Completeness (%)98.4 (97.5)100 (100)97.9 (98.5)Multiplicity1.8 (1.8)7.0 (7.1)3.3 (3.4)**Refinement**Resolution (Å)48.23--2.5060.14--2.8048.46--3.80No. reflections53,1989,27910,962*R*~work~/*R*~free~20.0/22.718.5/22.623.45/28.51*Clashscore*5.637.7011.63No. Atoms Protein10,4902,5877,123 Ligand/ion573436 Water105150*B* Factors Wilson *B*47.7456.6183.78 Protein56.6361.65126.41 Ligand/ion55.0984.3478.37 Water46.3850.41--Root-Mean-Square Deviations Bond lengths (Å)0.0050.0040.003 Bond angles (°)0.9960.850.67Ramachandran statistics (favored/allowed/outliers)98.7/1.3/099.1/0.9/097.9/2.1/0[^3]

Individually, however, the structures of affimer-bound diUb complexes are surprisingly distinct ([Figures 2](#fig2){ref-type="fig"}A--2I). In the K6 affimer, the first variable loop extends the existing β strands, whereas the second variable loop extends into an α-helical turn ([Figure S2](#mmc1){ref-type="supplementary-material"}D) that bridges to the second affimer molecule and engages in a strand swap of the last β strand. This leads to a symmetric dimer, similar to what has been found for naturally occurring cystatins ([@bib18]; [Figure S2](#mmc1){ref-type="supplementary-material"}E). L74, I105, M107, and M110 in the variable loops create a hydrophobic surface that interacts with the I44 patch of Ub (L8, I44, and V70; [Figure 2](#fig2){ref-type="fig"}C), and four salt bridges further strengthen this interaction ([Figure S2](#mmc1){ref-type="supplementary-material"}C).

In the K33 affimer, the mode of dimerization is different ([Figures 2](#fig2){ref-type="fig"}D--2F). Both variable loops extend the existing β strands, which leads to the formation of an intermolecular β sheet ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Ub interactions are mediated by the elongated β sheet and are centered on W105 that contacts the I44 patch ([Figure 2](#fig2){ref-type="fig"}F). Additionally, E76 forms a salt bridge with K6 of Ub ([Figure 2](#fig2){ref-type="fig"}F). The structure also indicates how the affimer could bind to longer K33 polymers ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Finally, we solved a 3.8-Å structure of the K33 affimer bound to K33 diUb in a different space group, which shows the same overall orientation and interactions ([Figure S2](#mmc1){ref-type="supplementary-material"}G).

Differently linked Ub chains adopt distinct conformations, and binding partners select a suitable one from the population of conformations each chain can adopt ([@bib61]). Crystal structures have captured some of these conformational states and reveal what a chain type can look like. Interestingly, whereas the affimer-bound K6 diUb does not resemble previous K6 crystal structures ([@bib16], [@bib52]; [Figure S2](#mmc1){ref-type="supplementary-material"}H), the affimer-bound K33 diUb superimposes well with reported K33 diUb crystal structures ([Figure S2](#mmc1){ref-type="supplementary-material"}I; [@bib22], [@bib31]). The latter also closely resembles a conformation adopted by K11 diUb ([@bib4], [@bib26]; [Figure 2](#fig2){ref-type="fig"}J), suggesting that the K33 affimer could be cross-specific with K11 polyUb. ITC measurements indeed confirm that the K33 affimer also dimerizes to bind K11 diUb tightly, with affinities slightly weaker than the K33 diUb but still in the low nM range ([Figure 2](#fig2){ref-type="fig"}K). As phage display selections and ITC measurements were all done in solution, this suggests that the observed conformations for K6, K33, and also K11 diUb exist in solution and that the affimer selects this particular conformation from the conformational ensemble.

Dimerized Affimers Show Improved Binding Characteristics {#sec2.3}
--------------------------------------------------------

The dimeric states of affimers in solution and in the crystal structures were further confirmed by size-exclusion chromatography with multi-angle light scattering (SEC-MALS). This showed that the K6 affimer alone is in a concentration-dependent monomer-dimer equilibrium, which is shifted fully toward the dimer by addition of diUb ([Figure 3](#fig3){ref-type="fig"}A). The strand swap observed in the K6 affimer crystal structure is likely responsible for the relatively stable dimer in the absence of diUb. In contrast, the K33/K11 affimer is monomeric and only dimerizes upon diUb binding ([Figure 3](#fig3){ref-type="fig"}B). This suggests that this affimer requires high concentrations to work, likely explaining the lack of signal in western blotting ([Figure S1](#mmc1){ref-type="supplementary-material"}E).Figure 3Affimers Dimerize to Achieve Linkage Specificity(A) SEC-MALS analysis of K6 affimer alone (gray) and with a 0.95 molar equivalent of K6 diUb (cyan). Observed molecular masses are shown with expected molecular masses in brackets.(B) As in (A) but for K33/K11 affimer alone (gray) and with K33 diUb (orange) or K11 diUb (magenta).(C) Microscale thermophoresis (MST) binding assay of dimerized K6 affimer against differently linked diUb. Data were fitted to a single-site binding model accounting for ligand depletion. Error bars represent mean ± SD.(D) As in (C) but for the K33/K11 affimer.(E) Silver stain input and western blot of purified diUbs with biotinylated, dimerized K6 affimer.(F) As in (E) but for tetraUb.(G) As in (E) but with the dimerized K33/K11 affimer. The silver stain input gel is the same as in (E).(H) As in (F) but for tetraUb. The silver stain input gel is the same as in (F).(I) Indicated amounts of K48 and K6 diUb were probed with dimerized K6 affimer.(J) As in (I) but with K48 and K33 diUb and probed with the dimerized K33/K11 affimer.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Biophysical and structural data collectively indicated that a covalent, constitutive affimer dimer may have improved binding characteristics. To test this, we truncated and fused the affimers, as guided by the structure, to generate tandem repeat dimeric affimers ([Figure S3](#mmc1){ref-type="supplementary-material"}A), and we characterized these dimerized versions biophysically. Binding equilibria were achieved within 2 hr and 1 hr for the K6 and K33/K11 affimer, respectively, even at concentrations of 5 nM that are comparable to or below concentrations used in subsequent applications ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C; see below). The binding affinities of these affimers for differently linked diUb were determined using fluorescence polarization (FP) and microscale thermophoresis (MST) assays. We found that the K6 affimer bound the cognate K6 diUb with very high affinity (*K*~*d*~ ∼20 pM) and has negligible affinity for the other diUb linkages (*K*~*d*~ \> 40 μM; [Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}D). Similarly, the K33/K11 affimer binds K33 and K11 diUb tightly (with a *K*~*d*~ of 47 pM and 1.6 nM, respectively) and again showed little binding to non-cognate diUbs (*K*~*d*~ \> 50 μM; [Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}E). In western blotting, the dimerized K6 affimer still recognized K6 polyUb specifically with very little background even at long exposures ([Figures 3](#fig3){ref-type="fig"}E and 3F). Furthermore, the dimerized K33/K11 affimer started to work in western blotting and detected K33, and to an ∼4-fold lesser extent K11 diUb, consistent with affinity data ([Figures 3](#fig3){ref-type="fig"}G, 3H, and [S3](#mmc1){ref-type="supplementary-material"}F). Western blotting with diUb titration suggests that the K6 and K33/K11 affimers prefer their cognate diUb ≥1,000-fold over other diUb linkages ([Figures 3](#fig3){ref-type="fig"}I, 3J, [S3](#mmc1){ref-type="supplementary-material"}G, and S3H). Due to the superior binding properties of the dimerized affimers, all subsequent experiments were performed with these improved versions.

Affimers Faithfully Detect Longer Ub Chains and Reveal E3 Ligase Specificities {#sec2.4}
------------------------------------------------------------------------------

To further characterize and exploit affimers, we used them to identify chain types assembled by E2 and E3 enzymes. To test this, Ub chains were assembled with the K11-specific E2 UBE2S ([@bib4]), the K11-/K33-specific HECT E3 ligase AREL1 ([@bib31]), and the K6-/K48-specific HECT-like E3 NleL ([@bib16]). HECT, HECT-like, and RBR E3s dictate the type of Ub linkage they assemble independently of the E2 used ([@bib62]), and for these families of E3 ligases, the E2 only serves to charge Ub onto the active site Cys. The E2 enzyme UBE2L3 is specific for this trans-thioesterification reaction ([@bib54]) and works well with HECT and RBR E3s.

UBE2S assembles K11 chains, and these were recognized by the K33/K11 affimer ([Figure 4](#fig4){ref-type="fig"}A). Whereas some conjugates were still formed using Ub K11R, the K33/K11 affimer did not recognize these products ([Figure 4](#fig4){ref-type="fig"}A), suggesting that these are not K33 conjugates. Similarly, the K33/K11 affimer also detected products of AREL1, which assembles mostly K11 and K33 chains with wild-type Ub, independently of which E2 is used ([@bib31]; [Figure 4](#fig4){ref-type="fig"}B). The signal slightly increased using a K11R Ub mutant and was reduced with a K33R Ub mutant ([Figure 4](#fig4){ref-type="fig"}B), in agreement with the preferred detection of K33 chains over K11 chains ([Figure S3](#mmc1){ref-type="supplementary-material"}F). NleL is a HECT-like effector E3 ligase from *E*. *coli* O157:H7 that assembles mixed and branched K6- and K48-linked chains *in vitro* ([@bib16]), and these chains were recognized by the K6-specific affimer ([Figure 4](#fig4){ref-type="fig"}C). Chains assembled with a Ub K6R mutant to prevent the formation of K6 chains yielded no K6 signal, whereas using Ub K48R increased the signal ([Figure 4](#fig4){ref-type="fig"}C), consistent with linkage-specific detection of K6 chains.Figure 4*In Vitro* Applications of Affimers(A) *In vitro* assembly reaction of the E2 UBE2S with Ub WT and Ub K11R with Coomassie (top) or blotted with the K33/K11 affimer (bottom).(B) *In vitro* assembly reaction of the HECT E3 AREL1 with Ub WT, Ub K11R, and Ub K33R stained with Coomassie (top) and probed by western blotting with the K33/K11 affimer (bottom). Longer chains are preferentially detected, probably due to avidity effects.(C) *In vitro* assembly reaction of the HECT-like E3 NleL with Ub WT, Ub K6R, and Ub K48R stained with Coomassie (top) or probed by western blotting with the K6 affimer (bottom).(D) *In vitro* Ub chain assembly reactions for RNF144A and RNF144B, with Ub WT, alongside recombinant diUb standards on silver stain (top) and probed with the K6 affimer (middle) and the K33/K11 affimer (bottom).(E) AQUA-MS-derived linkage composition of RNF144A-assembled total Ub chains at a 1 hr time point.(F) As in (E) but for RNF144B.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Next, we set out to characterize the products of ligases with unknown linkage specificities. Many RBR-type E3 ligases, including HOIP and Parkin, assemble atypical Ub chain types, but several others have remained unstudied. We tested the RBR E3 ligases RNF144A and RNF144B, both of which are uncharacterized with regards to their linkage specificity. The proteins are highly homologous, and both comprise an RBR domain and a C-terminal transmembrane domain. The isolated RBR domain of both RNF144A and RNF144B can be expressed in soluble form in *E. coli* and together with the E2 UBE2L3, they assemble free as well as conjugated Ub chains *in vitro* ([Figure 4](#fig4){ref-type="fig"}D). Western blotting revealed a strong signal with the K6- as well as with the K33-/K11-specific affimers, indicating that both ligases assembled these atypical chain types ([Figure 4](#fig4){ref-type="fig"}D). This warranted more detailed analysis by AQUA-based mass spectrometry (MS), which showed that RNF144A and RNF144B assembled predominantly K11 (47% and 62%, respectively) but also K6 (22% and 10%), K48 (25% and 10%), and K63 chains ([Figures 4](#fig4){ref-type="fig"}E, 4F, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B). This was further confirmed by linkage-specific antibodies ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D).

Affimers Detect K6 Chains in Cells {#sec2.5}
----------------------------------

Having shown that affimers are linkage specific *in vitro*, we set out to test them in a cellular context. We focused our studies on the K6 affimer as it was more specific, and K6 chains had been implicated in intriguing biological processes. The abundance of K6-linked chains is reportedly low at \<1% of all linkages ([@bib8]), which provided a challenging opportunity to study this chain type.

First, we generated a stable T-REx 293 cell line, in which a full-length, hemagglutinin (HA)-tagged version of the bacterial effector NleL is expressed in an inducible manner. Consistent with the low abundance of K6 chains, western blotting of whole-cell lysate (WCL) with the K6 affimer yielded no signal. This changed upon induced expression of NleL, which did not cause a global increase in total Ub conjugates but resulted in a strong signal with the K6 affimer ([Figure 5](#fig5){ref-type="fig"}A). Enriching all Ub conjugates using TUBEs ([@bib15]) improved the signal further and, interestingly, also enabled detection of K6 chains in non-induced cells ([Figure 5](#fig5){ref-type="fig"}A). This shows that the K6 affimer can be used to detect K6 chains in a cellular context and, with polyUb enrichment, even at endogenous levels.Figure 5*In Vivo* Applications of Affimers(A) HA-NleL 293 T-Rex cells were induced with 1 μg/mL doxycycline for 12 hr or left untreated. Whole-cell lysate (WCL) blots are shown for actin, HA(-NleL), Ub, and K6 chains. Western blots with the K6 affimer are also shown after Ub enrichment using TUBEs.(B) TUBE-PD of HEK293 cells after 1 hr of MG132 (10 μM) without further treatment (−) or with additional UV (40 J/m^2^) or CCCP treatment (10 μM for 1 hr) and subsequently blotted with the K6 affimer. Input controls are shown for total Ub and actin and γH2AX. The relative signal increase from two experiments is shown below the respective lanes.(C) Expression of WT or catalytically inactive (C431S) Parkin in HeLa Flp-In cells was induced with 0.2 μg/mL doxycycline for 16 hr. Mitochondria were depolarized with O/A for 2 hr. WCL inputs are shown for total Ub, expressed Parkin, TOM20, and actin. The TUBE-PD was also blotted using the K6 affimer and total Ub.(D) Confocal fluorescence microscopy images of cells as in (B) stained with K6 affimer (green), TOM20 (red), and DAPI (blue). Cells and a magnified area are outlined in white. Scale bars correspond to 20 μm.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Similar results were obtained with HEK293 cells, where K6 linkages could not be detected in WCL, even after 1 hr treatment with the proteasome inhibitor MG132 ([Figure 5](#fig5){ref-type="fig"}B). TUBE-mediated enrichment of polyUb enabled robust detection of endogenous K6 chains ([Figure 5](#fig5){ref-type="fig"}B). Consistent with previous reports, UV radiation (40 J/m^2^ with 1 hr recovery in medium containing 10 μM MG132, according to [@bib10]) or mitochondrial decoupling (10 μM CCCP for 1 hr in presence of 10 μM MG132) increased the K6 signal in TUBE pull-downs 2- to 3-fold ([Figure 5](#fig5){ref-type="fig"}B). This is consistent with recent data suggesting a 3- to 4-fold increase in K6 linkages upon DNA damage ([@bib10]) and 2- to 8-fold increase upon mitochondrial depolarization ([@bib7], [@bib36]). Importantly, whereas K6 linkages account for only a small fraction of linkages present, they are faithfully detected by the K6 affimer.

PINK1/Parkin-mediated mitophagy is emerging as a robust system for Ub studies. Parkin as well as the mitochondrial DUB USP30 regulate mitophagy in part by regulating K6-linked chains on mitochondria ([@bib7], [@bib9], [@bib36], [@bib64]). For this, HeLa Flp-In T-REx cells inducibly expressing wild-type (WT) or catalytically inactive (C431S) Parkin were depolarized with oligomycin/antimycin A (O/A), leading to robust Parkin-dependent ubiquitination of mitochondrial proteins, including TOM20 ([Figure 5](#fig5){ref-type="fig"}C; [@bib36], [@bib42]). Importantly, whereas there is no overall change in cellular Ub ([Figure 5](#fig5){ref-type="fig"}C), TUBE pull-down and blotting with the K6 affimer reveals an increase in K6 chains in a depolarization- and Parkin-dependent manner ([Figure 5](#fig5){ref-type="fig"}C). Blotting of the TUBE pull-down for total Ub shows equal amounts of Ub in all lanes ([Figure 5](#fig5){ref-type="fig"}C), further demonstrating that the differential signal observed in the K6 affimer blot is indeed due to K6 chains.

To further demonstrate the accumulation of K6 chains on mitochondria during mitophagy, we tested the utility of the K6 affimer in confocal fluorescence microscopy. Using site-specifically Alexa-488-labeled, dimeric K6 affimer on fixed, permeabilized cells, we observed that the K6 affimer displayed diffuse, mostly nuclear localization in untreated cells ([Figure S5](#mmc1){ref-type="supplementary-material"}A). However, upon depolarization using O/A, the K6 affimer relocalized to mitochondria in WT Parkin-reconstituted cells, but not in cells expressing Parkin C431S ([Figures 5](#fig5){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}B). This was accompanied by perinuclear clustering of depolarized mitochondria ([Figure 5](#fig5){ref-type="fig"}D), which has been previously reported ([@bib34]). Similar staining can be achieved with a total Ub conjugates antibody (FK2) because under these conditions, mitochondria are highly ubiquitinated ([@bib36]; [Figure S5](#mmc1){ref-type="supplementary-material"}B). However, the FK2 antibody also labels additional sites, e.g., in nuclei, that do not co-stain with K6 affimer ([Figure S5](#mmc1){ref-type="supplementary-material"}B), suggesting that the affimer retains at least some of its specificity under these conditions. To further test this, we treated cells with tumor necrosis factor alpha (TNF-α) to induce signaling complexes with high-density Ub modifications comprising K63 and M1 linkages ([@bib48]). These structures are labeled with FK2 anti-Ub and anti-NEMO antibodies, but not with the K6 affimer, indicating that these Ub-rich structures lack detectable amounts of K6 chains. This further suggests that the affimer has negligible off-target binding when used at suitable concentrations.

Using Affimers as Affinity Matrices for Mass Spectrometry {#sec2.6}
---------------------------------------------------------

In pull-down applications, the K6 affimer selects its cognate chain type from a mixture of K6, K48, and K63 tetraUb and shows no detectable off-target binding in absence of K6 linkages ([Figure 6](#fig6){ref-type="fig"}A). Similarly, the K33/K11 affimer quantitatively binds K33 and K11 diUb but fails to pull down K6 diUb ([Figure 6](#fig6){ref-type="fig"}B). This prompted us to establish a MS-compatible protocol for the enrichment of K6 linkages, in order to identify proteins modified with this chain type. PolyUb species captured on a K6 affimer matrix were subjected to AQUA MS analysis to determine the Ub linkage composition. Despite the high specificity observed *in vitro* ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [6](#fig6){ref-type="fig"}A), we were concerned about non-specific polyUb interactions and attempted to adjust the amount of affimer to expected amounts of cellular K6 linkages ([Figure 6](#fig6){ref-type="fig"}C). About 0.5% of the proteome of HEK293 cells is Ub, of which about 10% is in chains ([@bib20]). K6 linkages account for 0.5% of all Ub linkages in HEK293 cells ([@bib8]), and assuming that a 10-cm^2^ dish of HEK293 cells contains 2 mg total protein, about 500 ng of K6-linked Ub is expected for this amount of cells. We therefore performed affimer pull-downs from a 10-cm^2^ dish of HEK293 cell using 250 ng, 2.5 μg, and 25 μg K6 affimer, respectively ([Figures 6](#fig6){ref-type="fig"}D, 6E, [S6](#mmc1){ref-type="supplementary-material"}A, and S6B).Figure 6Enriching Ub Linkages Using Affimers(A) *In vitro*, competition pull-down with dimerized K6 affimer against differently linked tetraUb.(B) *In vitro* pull-down with biotinylated, dimerized K33/K11 affimer against different diUb linkages.(C) Schematic of pull-downs with varying amounts of GFP-tagged K6 affimer, either adjusted to expected amounts of K6 chains or in excess thereof.(D) Relative enrichment of the different chain types after K6 affimer pull-down using different amounts of affimers.(E) Total chain composition of pull-downs performed in (E) with 250 ng of K6 affimer.(F) Chain composition of K6 affimer pull-down with 250 ng K6 affimer and treating the pull-downs with 1 μM OTUB1 and 1 μM AMSH for 1 hr on ice.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

At the highest concentration of affimer (25 μg; 100-fold excess over estimated K6 chains), K6 chains are enriched ∼10-fold over their total cellular composition ([Figures 6](#fig6){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}A), enriched from ∼0.5% of linkages in cells (as detected in TUBE pull-downs \[not shown\] or according to [@bib8]) to 7%. Under these conditions, the majority of Ub linkages were K48 chains (64%), K63 chains (19%), and K11 chains (9%; [Figure S6](#mmc1){ref-type="supplementary-material"}A), reflecting those linkages most abundant in cells.

Rewardingly, reducing the amount of K6 affimers on the resin led to significant enrichment of K6 polyUb over other chain types: at the lowest affimer concentration (250 ng), K6 linkages were enriched 75-fold (enrichment from 0.5% to 37% of linkages detected; [Figures 6](#fig6){ref-type="fig"}D and 6E) and were now the second most abundant chain type in the pull-down (after K48 chains at 48%).

The presence of large amounts of other linkage types in the K6 affimer pull-down could have several reasons ([Figure S6](#mmc1){ref-type="supplementary-material"}C). To exclude that other chain types originate from co-purifying proteins, we performed pull-downs in presence of 0--8 M urea. At urea concentrations above 4 M, the amount of Ub detected was strongly reduced (not shown), suggesting that affimer:Ub interactions were not stable at high urea concentrations. Importantly, however, linkage compositions in pull-downs did not change appreciably at any urea concentration ([Figure S6](#mmc1){ref-type="supplementary-material"}D). This strongly suggested that co-purifying chains were attached to the same substrates that also contained K6 linkages, either as separate chains or in form of heterotypic (mixed or branched) chains. To further improve the enrichment of K6 linkages in the pull-down, beads were treated with improved versions of OTUB1 and AMSH ([@bib31]) to remove K48 and K63 chains, respectively. With this setup, K6 chains were the dominant chain type in the pull-down (56%), representing a \>100-fold enrichment of K6 linkages in the sample ([Figure 6](#fig6){ref-type="fig"}F).

HUWE1 Assembles K6 Chains *In Vitro* and *In Vivo* {#sec2.7}
--------------------------------------------------

In the established K6 enrichment protocols, proteins detected specifically in the affimer pull-down are likely modified with K6-linked chains. We hence performed shotgun proteomics on DUB-treated K6 affimer pull-downs ([Figure 6](#fig6){ref-type="fig"}E) to identify K6-polyubiquitinated proteins. Interestingly, the second most enriched protein (after Ub), and the only other protein observed in all three replicates, was the HECT E3 ligase HUWE1 (also known as Mule, ARF-BP1, LASU1, or HECTH9; [Figures 7](#fig7){ref-type="fig"}A, [S7](#mmc1){ref-type="supplementary-material"}A, and S7B). HUWE1 is a large (480 kDa) and highly abundant protein, mutations in which cause X-linked mental retardation syndromes ([@bib14]). Moreover, HUWE1 has been intensely studied in context of cancer, where it was assigned pro-oncogenic but also tumor-suppressive functions ([@bib43]). Its wide range of substrates implicate the protein in cellular processes, including DNA damage signaling ([@bib5], [@bib33], [@bib39]), cell death signaling ([@bib63]), and mitochondrial maintenance ([@bib44]), and most recently in quality control pathways relating to ribosome biogenesis ([@bib46], [@bib57]). HUWE1 is heavily posttranslationally modified, featuring numerous phosphorylation and ubiquitination sites. The finding that it is pulled down by the K6 affimers suggests that at least some of these ubiquitination events may involve K6-linked Ub chains.Figure 7HUWE1 Assembles K6 Chains *In Vitro* and *In Vivo*(A) Table summarizing proteins identified with the corresponding number peptide-spectrum matches (PSMs) in three replicates of DUB-treated K6 affimer pull-downs.(B) *In vitro* assembly reaction of the HECT E3 HUWE1 with Ub WT, Ub K6R, Ub K11R, and Ub K48R on Coomassie. Arrows indicate K6 diUb.(C) Linkage composition of HUWE1-generated diUb after 1 hr as determined by AQUA MS.(D) AQUA-derived total cellular chain composition of HUWE1^−/−^ HeLa and parental cells after TUBE-based enrichment. Error bars indicate mean ± SD from n = 3. ^∗^p \< 0.05, according to a two-tailed Student's t test. N.S., not significant.(E) TUBE-PD from a doxycycline-inducible HUWE1 shRNA Ls174T cell line blotted with the K6-specific affimer, with input controls for actin, total Ub, and HUWE1.(F) K6 affimer pull-down in doxycycline-inducible HUWE1 shRNA Ls174T cells blotted against Mfn2. Cells were left untreated or treated with 10 μg/mL MG132 for 4 hr and/or 1 μg/mL doxycycline for 72 hr. Pull-downs were incubated with 250 nM USP21 as indicated, with a K48 blot to show completeness of the deubiquitination reaction. Input controls are shown for Mfn2, actin, and HUWE1.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Many E3 ligases autoubiquitinate, and HECT E3s are known to assemble atypical Ub chains ([@bib22], [@bib31]). We therefore assessed which chain types HUWE1 generated *in vitro*. The recombinant HUWE1 HECT domain assembled free and conjugated Ub chains, and close inspection of the assembly patterns comparing Ub WT with Ub K6R indicated assembly of K6 linkages ([Figure 7](#fig7){ref-type="fig"}B). This was confirmed by western blotting with the K6 affimer ([Figure S7](#mmc1){ref-type="supplementary-material"}C), as well as by AQUA MS analysis. The latter, performed on the generated diUb, revealed that HUWE1 assembles K11 linkages (37%), K48 linkages (33%), K6 linkages (26%), and a small amount of K63 linkages (4%; [Figure 7](#fig7){ref-type="fig"}C), and similar results were obtained when the whole assembly reaction was analyzed ([Figure S7](#mmc1){ref-type="supplementary-material"}D). To test whether full-length HUWE1 also assembles K6 chains *in vivo*, we analyzed the linkage composition of total cellular Ub chains in HUWE1^−/−^ HeLa and parental control cell lines ([@bib5]). Surprisingly, K6 chains were significantly less abundant in HUWE1^−/−^ cell lines, showing a decrease of ∼75% ([Figure 7](#fig7){ref-type="fig"}D). The only other chain type that changed significantly was K11, showing a decrease of ∼18%. These results are consistent with a previous SILAC-based proteomic study aimed at identifying potential HUWE1 substrates, using a HEK293 cell line with doxycycline-inducible, short hairpin RNA (shRNA)-mediated knockdown of HUWE1 ([@bib49]). Extraction of Ub linkage data from the latter analysis confirmed the significant decrease in K6 chains upon knockdown of HUWE1 ([Figure S7](#mmc1){ref-type="supplementary-material"}E). This was further substantiated in an inducible, shRNA-mediated HUWE1 knockdown system established in the colon cancer cell line Ls174T ([@bib41]). TUBE pull-downs were analyzed by western blotting with the K6 affimer, and HUWE1 knockdown led to a decrease in K6 chains, whereas overall ubiquitination remained seemingly unaltered ([Figure 7](#fig7){ref-type="fig"}E). Together, this confirms that endogenous, full-length HUWE1 assembles K6 linkages (alongside K11 and K48 linkages) and is a major source of K6-linked chains in resting cells.

We next investigated ubiquitination of endogenous Mfn2, a known substrate of HUWE1 ([@bib23], [@bib44]). We performed K6 affimer pull-downs from inducible HUWE1 shRNA Ls174T cells to enrich K6 ubiquitinated proteins. Western blotting for Mfn2 in uninduced cells reveals a slower migrating, ubiquitinated Mfn2 species, which is more pronounced after MG132 treatment ([Figure 7](#fig7){ref-type="fig"}F). Knockdown of HUWE1 leads to a marked reduction of ubiquitinated Mfn2 in the K6 affimer pull-down, with or without proteasome inhibition ([Figure 7](#fig7){ref-type="fig"}F). This indicates that Mfn2 is indeed a HUWE1 substrate.

Interestingly, we found a further way to corroborate the presence of K6 chains on substrates. The highly active and non-specific DUB USP21 ([@bib60]) was unable to cleave K6 linkages when bound to the K6 affimer, but it remained active against other chain types ([Figures S7](#mmc1){ref-type="supplementary-material"}F and S7G). Similarly, the K33/K11 affimer fully protected K33 diUb and partially protected K11-linked diUb from USP21 cleavage ([Figure S7](#mmc1){ref-type="supplementary-material"}H). Incubation of the K6 affimer pull-down with USP21 cleaved non-K6 chains and hydrolyzed all K48 linkages (the second most abundant chain type in this pull-down) detected by a K48-specific antibody ([Figure 7](#fig7){ref-type="fig"}F). Importantly, USP21 treatment only slightly reduced the ubiquitinated Mfn2 signal, indicating that the affimer protected K6-modified Mfn2 from being deubiquitinated by USP21. This is the most direct evidence that HUWE1-mediated ubiquitination of Mfn2 involves K6-linked polyUb.

Discussion {#sec3}
==========

The past years have seen significant progress in the study of atypical Ub signals, yet some chain types, in particular K6, K27, K29, and K33, have remained poorly studied due to lack of tools. Here, we partially fill this gap by establishing linkage-specific affimers for K6 and K33/K11 linkages. The characterized affimers have comparable properties to available linkage-specific antibodies and are suitable for a broad range of applications.

The crystal structures of affimers bound to their cognate chain types revealed how the cystatin scaffold dimerizes to achieve linkage specificity. Moreover, we have been able to predict a cross-reactivity in a Ub-binding protein when we realized that the K33 diUb conformation adopted in the affimer complex is similar to a conformation that K11 diUb can adopt ([@bib4], [@bib26]). This insight supports the notion that the many distinct polyUb structures reported may each be individually meaningful and functional.

Whereas these affimers exhibit ∼10^6^-fold linkage specificity on the level of diUb, it is important to include appropriate controls when using these reagents in a cellular context to minimize off-target binding at the concentrations used in the particular assay. It should be established that global ubiquitination is unaffected (for example, after a stimulus) while there is a differential signal for the chain type in question. Also, DUB treatments should be used with caution---depending on where the Lys6 linkage is located (e.g., in distal parts of a mixed or branched chain), the signal for a K6-modified protein may inadvertently be lost. Ideal controls could include an ubiquitin replacement strategy ([@bib37], [@bib56]), although, e.g., K6R mutation affects assembly of other chain types, such as K11 chains ([@bib3]).

Further, we here identify three human E3 ligases, RNF144A, RNF144B, and HUWE1, that assemble K6/K11/K48 (and some K63) linkages. Parkin is a fourth ligase to assemble this linkage combination ([@bib9], [@bib36]). Our finding that loss of HUWE1 globally reduces the levels of K6 linkages indicates that we have identified a major ligase for this chain type. This is reminiscent of M1-linked chains, global levels of which are regulated by the RBR E3 ligase HOIP and the DUB OTULIN ([@bib11]). RBR ligases, such as Parkin, undergo sophisticated activation mechanisms and may only be active in particular cellular context or after certain stimulations ([@bib47]). Hence, like M1-linked chains, K6 linkages could be used as a precision signal in highly regulated contexts.

HUWE1 has been implicated in the degradation of numerous short-lived proteins, and its ability to assemble K6-/K11-/K48-linked polymers indicates that this chain configuration may be a powerful degradation tag. K11/K48 branched chains are an efficient proteasomal degradation signal ([@bib30]). Recent work on proteasomal Ub receptors has found a K6/K48 preference in Rpn1 ([@bib45]). Also, the structural requirement for *exo* cleavage of K6 polyUb by USP DUBs ([@bib29]) would not allow K6 chains to be cleaved en bloc by USP14 as recently proposed ([@bib24]), which may extend residence time and degradation efficiency of K6-modified substrates at the proteasome. Indeed, K6 linkages accumulate quickly after proteasomal inhibition ([@bib8]). Nonetheless, HUWE1 is involved in many other contexts (e.g., DDR or mitophagy) where K6-linked chains could serve other roles, such as adaptor functions. The tools and protocols presented here to study K6- (and also K33-) linked Ub chains will enable further functional analysis of these unstudied cellular signals and will lead to a better understanding of the Ub code.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**α-Actin (clone C4)MilliporeMAB1501R; RRID: [AB_2223041](nif-antibody:AB_2223041){#intref0010}α-HA (clone 3F10)Roche11867423001; RRID: [AB_390918](nif-antibody:AB_390918){#intref0015}α-UbNovus BiologicalsUbi-1; RRID: [AB_2238516](nif-antibody:AB_2238516){#intref0020}α-γH2AxMilliporeJBW301; RRID: [AB_310795](nif-antibody:AB_310795){#intref0025}α-HUWE1Bethyl LaboratoriesA300-486A; RRID: [AB_2264590](nif-antibody:AB_2264590){#intref0030}α-Mfn2Abcamab56889; RRID: [AB_2142629](nif-antibody:AB_2142629){#intref0035}α-K48 UbMilliporeApu2; RRID: [AB_1587578](nif-antibody:AB_1587578){#intref0040}α-K63 UbMilliporeApu3; RRID: [AB_1587580](nif-antibody:AB_1587580){#intref0045}α-TOM20Santa Cruz BiotechnologyFL-145/sc-11415; RRID: [AB_2207533](nif-antibody:AB_2207533){#intref0050}FK2MilliporeFK2; RRID: [AB_612093](nif-antibody:AB_612093){#intref0055}α-NEMOSanta Cruz BiotechnologyFL-419/sc-8330; RRID: [AB_2124846](nif-antibody:AB_2124846){#intref0060}HRP-conjugated StreptavidinCST3999; RRID: [AB_10830897](nif-antibody:AB_10830897){#intref0065}HRP-conjugated sheep α-mouseGE Life SciencesNA931; RRID: [AB_772210](nif-antibody:AB_772210){#intref0070}HRP-conjugated donkey α-rabbitGE Life SciencesNA934; RRID: [AB_772206](nif-antibody:AB_772206){#intref0075}Alexa 647-conjugated donkey α-mouseInvitrogenA31571; RRID: [AB_162542](nif-antibody:AB_162542){#intref0080}Alexa 594-conjugated donkey α-rabbitInvitrogenA21207; RRID: [AB_141637](nif-antibody:AB_141637){#intref0085}**Chemicals, Peptides, and Recombinant Proteins**K27 diUbUbiQUbiQ-015TNF-αInvitrogenPHC3016**Deposited Data**K6-affimer:K6 diUb structureThis paperPDB: [5OHL](pdb:5OHL){#intref0090}K33-affimer:K33 diUb structure (*H 3*)This paperPDB: [5OHV](pdb:5OHV){#intref0095}K33-affimer:K33 diUb structure (*P 2*~*1*~)This paperPDB: [5OHM](pdb:5OHM){#intref0100}**Experimental Models: Cell Lines**HEK293N/AN/ALs174T with HUWE1 shRNA[@bib41]\# 2HeLa parental[@bib5]N/AHeLa HUWE1 KO[@bib5]N/AT-REx 293 HA-NleLThis studyN/AFlp-In T-Rex HeLa Parkin wild-type[@bib36]N/AFlp-In T-Rex HeLa Parkin C431S[@bib36]N/A**Software and Algorithms**MicroCal ITC Origin Analysis softwareMalvernN/ASkyline[@bib25]N/AProteome DiscovererThermo ScientificN/A**Other**Protease inhibitor cocktailRoche11697498001MG132Sigma-AldrichC2211CCCPSigma-AldrichC2759EZ-Link Maleimide-PEG2-BiotinThermo Scientific21901BIDKOD HotStart PolymeraseNovagen71086In-Fusion HD Cloning KitClontech638918DNase ISigma-AldrichDN25LysozymeSigma-AldrichL6876TALON resinClontech635504Glutathione resinAmintraAGS0100BenzonaseNovagen70664NuPAGE 4%--12% Bis-Tris GelInvitrogenNP0322Trans-Blot Turbo Nitrocellulose MembraneBio-Rad1704158Alexa 488 C5 maleimideThermo ScientificA10254NT-647 maleimideNanoTemperMO-L004Dynabeads M-280 StreptavidinInvitrogen11205DAntimycin ASigmaA8674OligomycinMillipore495455

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Requests for further information or reagents should be directed to the lead contact and corresponding author, David Komander (<dk@mrc-lmb.cam.ac.uk>). Request for cell lines from other studies should be directed to the respective corresponding authors. Affimers can be obtained from Avacta (<https://www.avacta.com>).

Experimental Models and Subject Details {#sec4.3}
---------------------------------------

Ls174T cells were grown in RPMI1640 + 10% FCS (Fetal Calf Serum) +Pen/Strep, all other cell lines were grown in DMEM + 10% FCS + Pen/Strep. Cells were cultured at 37°C in a humidified atmosphere with 5% CO~2~.

Method Details {#sec4.4}
--------------

### Molecular Biology {#sec4.4.1}

DNA sequences were amplified using KOD HotStart DNA polymerase. RNF144A (aa 16-228) and RNF144B (aa 27-236) were cloned into pOPIN-K, which encodes a 3C-cleavable N-terminal His~6~-GST-tag using the In-Fusion HD cloning kit. Similarly, HUWE1 (aa 3993-4374) was cloned into pOPIN-B which encodes an N-terminal, 3C-cleavable His~6~-tag. Coding sequences for RNF144A and RNF144B are a gift from Christopher Sanderson (University of Liverpool) and HUWE1 from Mark Bycroft (MRC LMB). All constructs were verified by DNA sequencing.

### Protein Expression and Purification {#sec4.4.2}

RNF144A and RNF144B and HUWE1 were expressed in Rosetta2 (DE3) pLacI cells. Cells were grown from overnight cultures in 2xTY medium, supplemented with 35 μg/mL chloramphenicol and 50 μg/mL kanamycin. The cultures were cooled to 18°C prior to induction with 200 μM IPTG and expressed overnight. Pellets were resuspended in binding buffer (50 mM Tris pH 8.5, 150 mM NaCl, 2 mM β-mercaptoethanol). Prior to lysis by sonication, cell suspensions were supplemented with DNaseI, lysozyme and protease inhibitor cocktail. Proteins were bound to TALON metal affinity resin and washed using binding buffer supplemented with 5 mM imidazole. His~6~-GST-tags of pOPIN-B constructs were cleaved by addition of a His~6~-tagged 3C protease to beads at 4°C overnight. Eluted proteins were purified to homogeneity using size exclusion chromatography (HiLoad 16/60 Superdex 75, GE Life Sciences) in SEC buffer (20 mM Tris pH 8.5, 150 mM NaCl, 2 mM DTT). Peak fractions were concentrated, flash-frozen in liquid nitrogen and stored at −80°C.

HUWE1 ([@bib38]), Tandem UBA repeat TUBE ([@bib15]), Ub and E1, E2 and E3 enzymes and DUBs ([@bib31]) were purified as previously described. Except for K27 diUb (UbiQ), all Ub chains were produced enzymatically as previously described ([@bib4], [@bib16], [@bib31]).

Affimers are available from Avacta Life Sciences (Wetherby, UK).

### Western Blotting {#sec4.4.3}

For western blotting, biotinylated affimers were used. A single cysteine was introduced in the N terminus of the affimers to allow for site-specific labeling by Maleimide-PEG2-Biotin (the affimer scaffold does not contain any cysteines otherwise). 5 mg of affimer was labeled in 1 mL of labeling buffer (20 mM Tris pH 7.4, 150 mM NaCl, 2 mM TCEP) with 20-fold molar excess of biotin-maleimide for 4 hr at 4°C. The reaction was stopped with 20 mM β-mercaptoethanol. Excess biotin was removed using PD10 desalting columns (GE Life Sciences). Samples for blotting with the affimers were generally not boiled, as the affimers recognize folded Ub. After blotting, the nitrocellulose membrane was blocked in PBST containing 5% milk and incubated overnight at 4°C in 5% milk containing 0.1 μg affimer/mL. After a short wash in PBST, the blot was incubated for 1 hr with Streptavidin-HRP. For more sensitive detection, the blot was instead incubated for 1 hr at room temperature with an anti-biotin antibody, which was then incubated with a secondary, HRP-conjugated antibody. The signal was detected using Amersham ECL Prime reagent. Dilutions for all other western blotting reagents were 1:1,000, apart for Mfn2 (1:800), HA and actin (1:5,000) and HRP-conjugated secondaries (1:10,000).

### Isothermal Titration Calorimetry and Surface Plasmon Resonance {#sec4.4.4}

Isothermal titration calorimetry (ITC) experiments were carried out at 25°C on a MicroCal iTC200 instrument (GE Life Sciences). Monomeric affimers and diUbs were dialyzed against PBS buffer (18 mM Na~2~HPO~4~, 7 mM NaH~2~PO~4~ pH 7.2, 150 mM NaCl). Following a pre-injection of 0.5 μL of diUb, diUb (30 μM) was injected in 19 × 2 μL / 49 × 0.5 μL / 79 × 0.5 μL consecutive injections into the monomeric affimer sample (5 μM) in the cell at 120 s intervals. After removing the pre-injection data point, the resulting binding curves were fitted and binding constants calculated in MicroCal ITC Origin Analysis software (Malvern).

Surface plasmon resonance (SPR) experiments were performed on a Biacore 2000 (GE Life Sciences) as previously described ([@bib31]). Briefly, CM5 chips (GE Life Sciences) were activated, and functionalized by diUb injection at 100 ng/μL until 2000 response units were reached. For qualitative kinetic measurements, the samples were buffer exchanged into SPR buffer (20 mM Tris pH 7.4, 150 mM NaCl), and injected at 10 μM for 60 s followed by 150 s dissociation in SPR buffer at 20°C. Data were plotted in Prism 6.

### Fluorescence Polarization and Microscale Thermophoresis {#sec4.4.5}

Affimers were labeled site-specifically on a single cysteine with Alexa488-maleimide (for FP and MST measurements on the Monolith NT.115) or NT-647-maleimide (for MST measurements on the Monolith.NT115pico) according to the manufacturer's instructions. Free dye was removed and the protein buffer exchanged into MST buffer (20 mM Tris pH 7.4, 150 mM NaCl, 0.05% Tween-20). For FP assays, 500 pM of labeled affimer was incubated with varying concentrations of diUb for 3 hr before measurements were taken on a PheraStar plate reader (BMG Labtech), equipped with an optic module for detection of Alexa488 dye (λ~ex~ = 485 nm, λ~em~ = 520 nm) at 25°C. The polarization value of free, labeled affimer was determined by a spectrofluorometer and used for referencing raw data. For fitting, values were converted into anisotropy values and fitted with GraphPad Prism with the following single-site binding equation to account for ligand depletion:$$y = P_{min} + \left( {P_{max} - P_{min}} \right)\frac{\left( {L + K_{d} + x} \right) - \sqrt{\left( {- L - K_{d} - x} \right)^{2} - 4Lx}}{2L},$$where x is the concentration of diUb titrated and L the concentration of labeled affimer.

Kinetic association data were fitted using a one-phase association model described by$$y = P_{min} + \left( {P_{max} - P_{min}} \right)\left( {1 - e^{- kx}} \right),$$where x is time and k is the rate constant, and the half-time (τ) can be calculated by τ = ln(2)/k.

All MST measurements were performed on a Monolith NT.115 (NanoTemper) with 500 pM labeled affimer, except for binding assays involving dimeric affimers and their cognate diUb. These were performed on a Monolith NT.115Pico instrument to allow for lower concentration of fluorescently affimer used (50 pM) and therefore more precise binding assays. Measurements were performed in MST buffer at 100% LED power and 60% MST laser power. Curve fitting was performed on data derived from either thermophoresis or temperature jump, whichever was greater in amplitude. Data were fitted as described for FP. All assays were performed in at least n = 3.

### Crystallization, Data Collection, and Refinement {#sec4.4.6}

For crystals of K6-affimer bound to K6 diUb, 1 molar equivalent of K6-affimer was mixed with 1.2 molar equivalents of K6 diUb at a concentration of 8 mg/mL. Crystals grew at room temperature from a 2:1 (v/v) ratio of protein to reservoir solution containing 32.5% PEG 2000 MME, 200 mM ammonium acetate and 100 mM Tris pH 8.5. For vitrification, crystals were cryoprotected by transfer to a solution of mother liquor containing 28% glycerol.

For crystallization of the K33-affimer bound to K33 diUb, 1 molar equivalent of K33-affimer was mixed with 1.2 molar equivalents of K33 diUb at a final concentration of 5.7 mg/mL. Crystals grew by vapor diffusion at 4°C by mixing an equal volume of protein with 21 % PEG 3350, 200 mM LiSO~4~ and 100 mM sodium acetate pH 5.2. Prior to vitrification, crystals were cryoprotected in mother liquor containing 25% glycerol. The 3.8 Å K33-affimer:K33 diUb crystals in space group *P2*~*1*~ were grown at room temperature in 1:1 ratio of protein and 20% PEG 3350 and 200 mM KSCN and cryoprotected in mother liquor containing 20% glycerol.

Diffraction data were collected at ESRF beamline ID23-2 and Diamond Light Source beamlines I04 and I04-1. Diffraction data were integrated using XDS ([@bib19]) and scaled using AIMLESS ([@bib13]). Structures of higher resolution than 3 Å were solved by molecular replacement using truncated versions of the Adhiron scaffold (PDB: [4N6U](pdb:4N6U){#intref0115}) and Ub (PDB: [1UBQ](pdb:1UBQ){#intref0120}) as search models in PHASER ([@bib28]), whereas the 3.8 Å K33-affimer:K33 diUb structure was solved by molecular replacement using the higher resolution structure of the complex. Both crystal forms of the K33-affimer complex were multiple, and diffraction patterns showed a second, weakly diffracting lattice, which resulted in high *R*~*merge*~ values. Iterative rounds of manual model building and computational refinement were performed using COOT ([@bib12]) and PHENIX ([@bib1]), respectively. All structural figures were created in PyMOL (<http://www.pymol.org>). Final statistics can be found in [Table 1](#tbl1){ref-type="table"}.

### SEC-MALS {#sec4.4.7}

SEC-MALS measurements were performed using a Wyatt Dawn Heleos-II angle light scattering instrument connected to a Wyatt Optilab rEX online refractive index detector. Samples were diluted in SPR buffer to 200 μM for affimer only samples and to 118 μM affimer: 57 μM diUb for other samples, respectively. 100 μL of the diluted samples were run at 0.5 mL/min on an analytical gel filtration column (Superdex 75 10/300 GL, GE Life Sciences), before passing through the light scattering and refractive index detectors in a standard SEC-MALS format. Protein concentration was determined from the excess refractive index based on 0.19 RI for 1 mg/mL, and combined with the observed scattered intensity at each point in the chromatograms to calculate absolute molecular mass using Wyatt's ASTRA analysis software.

### Small-Scale Ub Assembly and Disassembly Reactions {#sec4.4.8}

Ub chains were assembled in a reaction containing 0.1 μM E1, 2.5 μM E2, 2.5 μM E3 and 30 μM Ub variant in assembly buffer (50 mM Tris pH 8.0, 10 mM MgCl~2~, 0.6 mM DTT, 10 mM ATP, 5% glycerol) at 37°C for the indicated times. For DUB assays, 10 μM diUb was incubated with 250 nM USP21 in DUB buffer (50 mM Tris pH 7.5, 50 mM NaCl, 5 mM DTT) at 37°C in the presence or absence of 12 μM dimeric K6-affimer-GFP. Reactions were stopped by addition of 4x SDS loading dye.

### Ub Chain Composition Analysis (AQUA) {#sec4.4.9}

Mass spectrometry analyses were performed as previously described ([@bib31], [@bib53]). Briefly, samples were resolved in a SDS-PAGE gel before being excised and diced into 1 mm^3^ pieces. Samples were digested with trypsin for 16 hr at 37°C after which 400 fmoles of isotopically labeled standards corresponding to each ubiquitinated peptide was added to the digestion reaction. Peptides were extracted from the gel slices, lyophilized, and resuspended in reconstitution buffer (7.5% acetonitrile, 0.5% TFA, 0.01% H~2~O~2~). Samples were separated using a Dionex Ultimate 3000 HPLC system with an EASY-Spray column (C18, 3 μm, 100Å, 75 μm x 15 μm) and analyzed on a Q Exactive (Thermo Scientific) using a parallel reaction-monitoring assay. Transition ions for the heavy and light peptides were quantified using Skyline ([@bib25]).

### Generation of NleL Cell Lines {#sec4.4.10}

To create T-REx 293 Ha-NleL cell lines, pcDNA4/TO/N-2xHA containing full-length, codon-optimized NleL was linearized using ScaI and transfected into T-REx 293 cells (Invitrogen). Cells were selected with 150 μg/mL zeocin and individual colonies were expanded and screened for NleL expression by western blotting with an HA-antibody. NleL expression was induced with 1 μg/mL doxycycline for 12 hr at 70% confluency and TUBE pull-downs were performed as described below.

### TUBE Pull-Downs {#sec4.4.11}

Cells were grown to 80% confluency. One 10 cm^2^ plate was lysed in 1 mL TUBE buffer (1% NP-40, 2 mM EDTA, 10 mM chloroacetamide, 100 μg/mL GST-tagged tandem UBA repeat TUBE ([@bib15]), protease inhibitor cocktail in PBS) with sonication. After clearing by centrifugation, the lysate was incubated on a spinning wheel overnight at 4°C. 40 μL of glutathione beads were added and incubated for 1 hr. Beads were washed 4 times with 1 mL of PBST.

### Confocal Fluorescence Microscopy {#sec4.4.12}

Inducible HeLa Flp-In T-REx cells expressing wild-type or catalytically inactive (C431S) Parkin (a kind gift of A. Ordureau & W. Harper (Harvard)) were seeded onto coverslips and expression was induced the next day with 0.2 μg/ml doxycycline for 16 hr. Mitochondria were depolarized using a combination of 4 μM Antimycin A and 10 μM Oligomycin for 2 hr. For TNFα experiments, HeLa cells were grown on coverslips and treated for 12 min with 10 ng/ml TNFα, before saponin extraction according to Tarantino et al., 2014. Cells for both sets of experiments were fixed using 4% paraformaldehyde, blocked using blocking buffer (5% goat serum and 0.2% Triton X-100 in PBS) and incubated overnight at room temperature in blocking buffer containing Alexa488-labeled dimerized K6-affimer (0.25 μg/ml), rabbit α-TOM20 (1:100) and FK2 (1:500) antibodies. After three washes in PBS, slides were incubated for 1 hr at room temperature in blocking buffer containing anti-mouse Alexa647- and anti-rabbit Alexa594-labeled antibodies (1:1000 each). Coverslips were mounted onto slide using Prolong Diamond Antifade mounting medium, sealed with nail polish and stored at 4°C. Imaging was performed on a Zeiss 780 with 63x magnification.

### Affimer Pull-Downs {#sec4.4.13}

HEK293 cells were grown to confluency and incubated for 1 hr with 10 μM MG132, scraped in lysis buffer (100 mM Tris pH 8.0, 50 mM NaCl, 0.5% NP-40, 10 mM chloroacetamide, protease inhibitor cocktail, 1 mM PMSF, 50 U/mL benzonase, 5 % glycerol) containing the indicated amounts of GFP-tagged dimeric K6-affimer. Cell lysates were cleared and incubated overnight at 4°C. 5-15 μL GFP-trap beads (Chromo-Tek) were added and incubated for 1 hr at 4°C. The beads were then washed 5 times in lysis buffer containing 150 mM NaCl, and 1x with lysis buffer containing 500 mM NaCl. For samples treated with DUBs, 1 μM of improved AMSH and OTUB1 ([@bib31]) were added and incubated for 1 hr at room temperature.

For Mfn2 ubiquitination experiments, Ls174T cells expressing a doxycycline-inducible shRNA targeting HUWE1 ([@bib41]) were grown to 50% confluency and shRNA expression was induced by 1 μg/mL doxycycline for 72 hr. The medium containing doxycycline was replaced every 24-48 hr. Prior to lysis, cells were treated for 4 hr with 10 μg/mL MG132, as indicated. Per condition, 2 × 15 cm^2^ dishes were lysed in lysis buffer containing 5 μg GFP-K6-affimer/mL. After washing the beads, 250 nM USP21 was added to beads at 4°C for 1 hr, as indicated.

For pull-downs with the K33/K11-affimer, 200 nM diUb was incubated with 200 nM site-specifically biotinylated K33/K11-affimer overnight in PBS. 10 μL of Dynabeads M-280 Streptavidin was added per sample, incubate for 1 hr at 4°C and samples were washed 5 x with PBST.

Proteins were eluted by boiling the samples in 4X LDS sample buffer, resolved by SDS-PAGE, transferred onto a nitrocellulose membrane and blotted as described above.

### Shotgun Proteomics {#sec4.4.14}

Peptides for discovery proteomics were separated identically to the Ub AQUA analysis. However, a Top10 analysis was performed. Precursor masses were screened using the following settings: mass range, 200-2000 m/z; resolution, 70,000, AGC target, 1E6; maximum ion trap time, 250 ms; scan-type, positive. Data-dependent settings include the following: resolution, 17,500, AGC target, 5E4; maximum ion trap time, 80 ms; isolation window, 2.0 m/z; collision energy, 28.0; data type, centroid; exclusion of unassigned charge states and masses with a charge state of 1. Dynamic exclusion enabled, 30 s. Raw files were searched and spectra assigned using SEQUEST against a human genome database (UniProt) in Proteome Discoverer (Thermo Scientific) with a false-discovery rate of 1%.

Quantitation and Statistical Analyses {#sec4.5}
-------------------------------------

Western blots were quantified in ImageJ by normalizing on the actin signal. All error bars are represented as mean ± standard deviation. Statistical significance was calculated using a two-tailed Student's t test and significance is denoted as followed: N.S not significant, ^∗^ p \< 0.05, ^∗∗∗^ p \< 0.001.

Data and Software Availability {#sec4.6}
------------------------------

Crystal structures have been deposited on the Protein Databank (PDB) under the following accession codes: K6-affimer:K6 diUb (*P* 1, PDB: [5OHL](pdb:5OHL){#intref0130}), K33-affimer:K33 diUb (*H* 3, PDB: [5OHV](pdb:5OHV){#intref0135}), K33-affimer:K33 diUb (*P* 2~1~, PDB: [5OHM](pdb:5OHM){#intref0140}).
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